PRIMR

Kidney cancer treatment depends on factors like overall health, tumor size, location, and risk of spread.

In this video, we cover various treatment options for kidney cancer that hasn’t spread, ranging from surgery to active surveillance.

Learn more:
https://www.primrmed.com/cancer-education/kidney-cancer-focal-therapy

PRIMR helps sponsors stay vigilant against engagement pitfalls with predictive analytics for clinical trials. 🧐🚀

https://www.primrmed.com/

Equip teams for trial success with PRIMR’s engaging videos.

Accurate info that patients love and understand. 🎬🔍

https://www.primrmed.com/

The American Society of Clinical Oncology (ASCO) fuels next-gen therapies.

On Day 5 of , we're featuring the SAMURAI trial, testing stereotactic ablative radiotherapy plus immunotherapy in unresected metastatic RCC to improve outcomes.

Watch the IRB-approved video:
https://www.primrmed.com/cancer-clinical-trials/samurai-trial

Produced in collaboration with NRG Oncology | William A. Hall, MD | Rana McKay.

The American Society of Clinical Oncology (ASCO) expands options for targeted neuro-oncology care.

On Day 5 of , we're featuring the FRONTIER study, evaluating Yttrium-90 internal radiation for recurrent GBM.

Watch the IRB-approved video:
https://www.primrmed.com/cancer-clinical-trials/frontier-trial

Produced in collaboration with Boston Scientific Urology | Boston Scientific Peripheral Interventions | Boston Scientific Urology .

The American Society of Clinical Oncology (ASCO) champions treatment that protects quality of life.

On Day 4 of , we're spotlighting the IRRADIANT trial, comparing a new IRE boost to standard RT for intermediate-risk prostate cancer to evaluate efficacy and toxicities.

Watch the IRB-approved video:
https://www.primrmed.com/cancer-clinical-trials/irradiant

Produced in collaboration with Memorial Sloan Kettering Cancer Center | Himanshu Nagar | AngioDynamics | The Nano Knife System.

The American Society of Clinical Oncology (ASCO) is redefining the standards of combination therapy.

On Day 4 of , we're sharing the STRIKE trial, testing if adding tivozanib to pembrolizumab reduces recurrence for advanced kidney cancer after surgery or ablation.

Watch the IRB-approved video:
https://www.primrmed.com/cancer-clinical-trials/strike

Produced in collaboration with the Alliance for Clinical Trials in Oncology | AVEO Oncology.